Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Sep 19;4(9):e247.
doi: 10.1038/bcj.2014.66.

Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion

A Maurizot  1 , J-P Beressi  2 , B Manéglier  3 , N H de la Marre  4 , M Spentchian  3 , P Soury  5 , P Solvet-Sebire  6 , C Collet-Gaudillat  2 , J-M Baud  1 , B Livarek  1 , F Guilhot  7 , P Rousselot  8
Affiliations
Case Reports

Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion

A Maurizot et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Imaging of the right femoral superficial artery stenosis by (a) Doppler ultrasound and (b) CTA associated with a distal arteriopathy (left image) and intra-stent stenosis (right image) diagnosed after angioplasty.
See this image and copyright information in PMC

References

    1. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533–539. - PubMed
    1. Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011;103:1347–1348. - PubMed
    1. Quintas-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12:337–340. - PubMed
    1. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86:610–611. - PubMed
    1. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26:2197–2203. - PubMed

MeSH terms